Shanghai Shyndec Pharmaceutical マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Yong Liu

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	2yrs
取締役会の平均在任期間	3.6yrs

経営陣の近況

Recent updates

Here's Why We Think Shanghai Shyndec Pharmaceutical (SHSE:600420) Is Well Worth Watching

Nov 17

Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Shares Fly 35% But Investors Aren't Buying For Growth

Oct 08

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?

Aug 23

Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified

May 06

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?

Apr 30

Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)

Apr 05

CEO（最高経営責任者

Yong Liu (55 yo)

less than a year

在職期間

Mr. Yong Liu is Vice Chairman of the Board of Shanghai Shyndec Pharmaceutical Co., Ltd. from April 28, 2021 and serves as President Since September 2024.

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Yong Liu	Vice Chairman of the Board & President	less than a year	データなし	データなし
Xian Lin Li	VP & General Counsel	2.6yrs	CN¥1.43m	0.0015% CN¥ 244.4k
Dongsong Wei	VP & Secretary of the Board of Directors	13.3yrs	CN¥1.46m	0.0015% CN¥ 244.4k
Feng Ni	Vice President	2yrs	CN¥914.60k	0.0015% CN¥ 244.4k
Jing Zu	Chief Financial Officer	less than a year	CN¥344.90k	データなし

2.0yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: 600420の経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Yong Liu	Vice Chairman of the Board & President	3.6yrs	データなし	データなし
Yingqi Li	Independent Director	2yrs	CN¥240.00k	データなし
Peng Wang	Director	2yrs	データなし	データなし
Ru Li	Director	2yrs	データなし	データなし
Zenghe Dong	Chairman	5.8yrs	データなし	データなし
Xiangdong Yu	Supervisor	5.8yrs	データなし	0.0015% CN¥ 244.4k
Kan Tian	Independent Director	5.8yrs	CN¥240.00k	データなし
Yonggang Xing	Chairman of the Supervisory Board	5yrs	データなし	データなし
Shuyuan Wei	Director	4.5yrs	データなし	データなし
Fanhong Wu	Independent Director	3.6yrs	CN¥240.00k	データなし
Yonghua Zuo	Supervisor	2yrs	データなし	データなし

3.6yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: 600420の取締役会は経験豊富であると考えられます ( 3.6年の平均在任期間)。

Shanghai Shyndec Pharmaceutical マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Here's Why We Think Shanghai Shyndec Pharmaceutical (SHSE:600420) Is Well Worth Watching

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Shares Fly 35% But Investors Aren't Buying For Growth

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?

Investor sentiment improves as stock rises 17%

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)

Full year 2023 earnings: EPS exceeds analyst expectations

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in FY 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

First quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.076 in 1Q 2022)

Investor sentiment improves as stock rises 20%

Full year 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in FY 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd. announced that it has received CNY 1.199999999 billion in funding from China National Pharmaceutical Group Corporation

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.20 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.20 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.20 in 2Q 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

First quarter 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.21 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.55 (vs CN¥0.63 in FY 2020)

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.30 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.63 (vs CN¥0.62 in FY 2019)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: CN¥8.47

New 90-day low: CN¥9.01

New 90-day low: CN¥9.42

New 90-day high: CN¥10.68

Third quarter earnings released

New 90-day low: CN¥9.49

First half earnings released

New 90-day high - CN¥10.64

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24